Drugs / Arlocabtagene Autoleucel
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06121843 | Feb 2024 → Aug 2028 expected | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 1 | NCT04674813 | Feb 2021 → Dec 2025 | plasma cell myeloma | Juno Therapeutics, a Subsidiary of Celgene | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06297226 | Mar 2024 → Jul 2026 overdue | plasma cell myeloma | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06615479 | Mar 2025 → Dec 2027 expected | refractory plasma cell neoplasm | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-09-08 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces Positive Topline Results from Registrational Phase 2 QUINTESSENTIAL Trial of the Potential First-in-Class GPRC5D-Directed CAR T Cell Therapy, Arlocabtagene Autoleucel ... bms.com ↗
Bristol Myers Squibb (NYSE: BMY) today announced positive Phase 2 results from the registrational QUINTESSENTIAL trial (NCT06297226) of arlocabtagene autoleucel (arlo-cel; BMS-986393) in adult patients with quadruple-class exposed relapsed and refractory multiple myeloma (RRMM). |
| 2024-12-09 | Bristol-Myers Squibb | Results Bristol Myers Squibb Highlights Progress of Cell Therapy Portfolio at ASH 2024 with Long-Term Survival Data and Results from Expanding Pipeline bms.com ↗
Bristol Myers Squibb (NYSE: BMY) announced results from 18 presentations reinforcing its leadership in cell therapy, with data demonstrating efficacy, durability and safety of currently available therapies in blood cancers and highlighting the potential of its pipeline for future indications including autoimmune diseases. |
| 2024-11-19 | Bristol-Myers Squibb | Results Bristol Myers Squibb’s Presentations at ASH 2024 Reinforce Strength of Hematology Portfolio and Scientific Advances in Differentiated Research Platforms bms.com ↗
First OS and progression-free survival results from a Phase 1 study of GPRC5D-directed CAR T cell therapy (BMS-986393/CC-95266) across all dose levels, supporting first-in-class potential in both B-cell maturation antigen (BCMA)-naïve and BCMA-exposed patients with RRMM |
| 2024-05-23 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms bms.com ↗
First results from the Phase 1 study of GPRC5D-directed CAR T cell therapy (BMS-986393/CC-95266) showcasing promising preliminary efficacy and safety outcomes with a single infusion of BMS-986393 in patients with relapsed or refractory multiple myeloma, including in patients with prior BCMA-directed therapy, who have received one to three prior regimens. |
| 2023-12-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs bms.com ↗
Updated data from the Phase 1 study of CAR T BMS-986393, a potential first-in-class cell therapy targeting GPRC5D, show deepening responses, a tolerable safety profile, and activity across both B-cell maturation antigen (BCMA)-naïve and -exposed patients |
| 2023-05-11 | Bristol-Myers Squibb | Results Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023 bms.com ↗
Interim results from Phase 1 study of GPRC5D CAR T (BMS-986393/CC-95266) demonstrated durable responses with an overall generally manageable safety profile, including in patients with prior BCMA-directed therapy. |
| 2023-02-02 | Bristol-Myers Squibb | Results Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2022 bms.com ↗
First disclosure of Phase 1 study for GPRC5D CAR T (BMS-986393/CC-95266) demonstrating deep and durable responses with a manageable safety profile across all dose levels, including patients previously treated with a B-cell maturation antigen-directed CAR T cell therapy. |
| 2022-12-12 | Bristol-Myers Squibb | Results Bristol Myers Squibb Announces First Disclosures and New Data at ASH 2022, Demonstrating Commitment to Raising Standards in Treatment Through Broad Multiple Myeloma Portfolio bms.com ↗ |
All press releases naming this drug 8 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Arlocabtagene Autoleucel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06297226 ↗ |
| Known as | Arlocabtagen autoleucel | ChEMBL registry synonym — accepted as the source's own label CHEMBL6068435 ↗ |
| Known as | BMS-986393 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06121843 ↗ |
| Known as | CC-95266 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04674813 ↗ |
| Modality | Cell therapy | “GPRC5D-directed CAR T Cell Therapy” NCT06297226 ↗ |
| Target | GPRC5D | “GPRC5D-directed CAR T Cell Therapy” NCT06297226 ↗ |